Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients.
Fiche publication
Date publication
janvier 2023
Journal
Therapeutic advances in medical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Dr ROYER Bernard
Tous les auteurs :
Callon S, Brugel M, Botsen D, Royer B, Slimano F, Feliu C, Gozalo C, Konecki C, Devie B, Carlier C, Daire V, Laurés N, Perrier M, Djerada Z, Bouché O
Lien Pubmed
Résumé
Dihydropyrimidine dehydrogenase (DPD) deficiency screening is a pre-therapeutic standard to prevent severe fluoropyrimidine-related toxicity. Although several screening methods exist, the accuracy of their results remains debatable. In France, the uracilemia measurement is considered the standard in DPD deficiency screening. The objective of this study was to describe the hyperuracilemia (⩾16 ng/mL) rate and investigate the influence of hepatic and renal impairment in uracilemia measurements since the guidelines were implemented.
Mots clés
dihydropyrimidine dehydrogenase deficiency, false-positive reactions, fluorouracil, kidney failure, liver function tests, uracil
Référence
Ther Adv Med Oncol. 2023 01 10;15:17588359221148536